Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Stutters

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Neurology|March 12, 2022
Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple SclerosisAlberto Calvi, Ferran Prados Carrasco, Carmen Tur, et al.
Annals of Clinical and Translational Neurology|September 18, 2022
Remyelination varies between and within lesions in multiple sclerosis following bexaroteneJ William L Brown, Ferran Prados, Daniel R Altmann, et al.
Journal of Magnetic Resonance Imaging : JMRI|October 3, 2023
Longitudinal Metabolite Changes in Progressive Multiple Sclerosis: A Study of 3 Potential Neuroprotective TreatmentsNevin A John, Bhavana S Solanky, Floriana De Angelis, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 9, 2021
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension studyHans-Peter Hartung, Tobias Derfuss, Bruce Ac Cree, et al.
Brain Communications|July 13, 2026
Investigating the treatment of vascular risk with simvastatin in secondary progressive multiple sclerosis: analysis from the MS-STAT2 randomized controlled trialThomas Williams, Nicholas Magill, Nevin A John, et al.
BMJ Open|September 1, 2018
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosisPeter Connick, Floriana De Angelis, Richard A Parker, et al.
The Lancet. Neurology|January 26, 2020
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trialJeremy Chataway, Floriana De Angelis, Peter Connick, et al.
Nature Communications|April 8, 2025
Enabling new insights from old scans by repurposing clinical MRI archives for multiple sclerosis researchPhilipp Goebl, Jed Wingrove, Omar Abdelmannan, et al.
The Lancet. Neurology|August 21, 2021
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a studyJ William L Brown, Nick G Cunniffe, Ferran Prados, et al.
BMJ Neurology Open|September 12, 2024
Brain reserve and physical disability in secondary progressive multiple sclerosisNevin John, Yingtong Li, Floriana De Angelis, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Neurology|March 12, 2022
Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple SclerosisAlberto Calvi, Ferran Prados Carrasco, Carmen Tur, et al.
Annals of Clinical and Translational Neurology|September 18, 2022
Remyelination varies between and within lesions in multiple sclerosis following bexaroteneJ William L Brown, Ferran Prados, Daniel R Altmann, et al.
Journal of Magnetic Resonance Imaging : JMRI|October 3, 2023
Longitudinal Metabolite Changes in Progressive Multiple Sclerosis: A Study of 3 Potential Neuroprotective TreatmentsNevin A John, Bhavana S Solanky, Floriana De Angelis, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 9, 2021
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension studyHans-Peter Hartung, Tobias Derfuss, Bruce Ac Cree, et al.
Brain Communications|July 13, 2026
Investigating the treatment of vascular risk with simvastatin in secondary progressive multiple sclerosis: analysis from the MS-STAT2 randomized controlled trialThomas Williams, Nicholas Magill, Nevin A John, et al.
BMJ Open|September 1, 2018
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosisPeter Connick, Floriana De Angelis, Richard A Parker, et al.
The Lancet. Neurology|January 26, 2020
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trialJeremy Chataway, Floriana De Angelis, Peter Connick, et al.
Nature Communications|April 8, 2025
Enabling new insights from old scans by repurposing clinical MRI archives for multiple sclerosis researchPhilipp Goebl, Jed Wingrove, Omar Abdelmannan, et al.
The Lancet. Neurology|August 21, 2021
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a studyJ William L Brown, Nick G Cunniffe, Ferran Prados, et al.
BMJ Neurology Open|September 12, 2024
Brain reserve and physical disability in secondary progressive multiple sclerosisNevin John, Yingtong Li, Floriana De Angelis, et al.
Pageof 2